Practical and Scalable Synthesis of Cisatracurium Besylate
Pharmaceutical Fronts · 01.09.2025 · 07 (03) · e210-e218
DOI: 10.1055/a-2673-5110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.09.2025. Verfasst von Yuchen Meng und 4 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cisatracurium besylate (1) is a potent nondepolarizing neuromuscular blocking agent utilized in clinical anesthesia. Its primary synthetic challenges arise from its four chiral centers and its unstable properties. We herein attempt to explore a practical and scalable method for the enantioselective synthesis of 1. In this work, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline (8) was used as a starting material. R-tetrahydropapaverine (R-6) was generated through a Ru-catalyzed asymmetric transfer hydrogenation reaction with 77.0% yield, 99.45% purity, and 99.67% ee. This was a key step. The control of the chiral nitrogen can be achieved through an N-methylation process to produce (R-cis)-10 with 41.6% yield, 99.08% purity, and gratifying enantioselectivity (100% de) through a simple and repeatable recrystallization. The process can be utilized to produce 1 without chromatography purification in five steps with an HPLC purity of 98.71% on a 100-g scale. The process was easy to implement and suitable for manufacturing-scale production.
Zitieren
APA
Meng, Y., Huang, R., Peng, P., Zhao, C., & Zhang, F. (2025). Practical and Scalable Synthesis of Cisatracurium Besylate. Pharmaceutical Fronts, 07(03), e210-e218. https://doi.org/10.1055/a-2673-5110
Vancouver
Meng Y, Huang R, Peng P, Zhao C, Zhang F. Practical and Scalable Synthesis of Cisatracurium Besylate. Pharmaceutical Fronts. 2025;07(03):e210-e218. doi:10.1055/a-2673-5110
BibTeX
@article{Meng2025,
author = {Meng, Yuchen and Huang, Renfu and Peng, Peng and Zhao, Chuanmeng and Zhang, Fuli},
title = {Practical and Scalable Synthesis of Cisatracurium Besylate},
journal = {Pharmaceutical Fronts},
year = {2025},
volume = {07},
number = {03},
pages = {e210--e218},
doi = {10.1055/a-2673-5110}
}
EUVIMED